fentanyl has been researched along with Constipation in 32 studies
Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078)
fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.
Constipation: Infrequent or difficult evacuation of FECES. These symptoms are associated with a variety of causes, including low DIETARY FIBER intake, emotional or nervous disturbances, systemic and structural disorders, drug-induced aggravation, and infections.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the efficacy and safety of transdermal fentanyl (TDF) and sustained release morphine (SRM) in strong-opioid naïve patients with chronic low back pain (CLBP)." | 9.11 | Transdermal fentanyl versus sustained release oral morphine in strong-opioid naïve patients with chronic low back pain. ( Allan, L; Richarz, U; Simpson, K; Slappendel, R, 2005) |
| "Constipation and the use of laxatives were investigated in patients with chronic cancer pain treated with oral morphine and transdermal fentanyl in an open sequential trial." | 9.09 | Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine. ( Grond, S; Kasper, M; Kulbe, C; Lehmann, KA; Loick, G; Radbruch, L; Sabatowski, R, 2000) |
| "Transdermal Fentanyl (TF, Durogesic) is a strong opioid analgesic which is used in the treatment of cancer pain." | 9.09 | [Research from the Palliative Care Department in Poznań on treatment of neoplasm pain with Durogesic (transdermal fentanyl)]. ( Gorzelińska, L; Kozikowska, J; Leppert, W; Luczak, J, 2000) |
| "The findings indicate comparability of transdermal buprenorphine and transdermal fentanyl for pain measures with significantly fewer adverse events (nausea and treatment discontinuation due to adverse events) caused by transdermal buprenorphine." | 8.88 | Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain. ( Aune, D; Hernandez, AV; Kleijnen, J; Misso, K; Riemsma, R; Truyers, C; Wolff, RF, 2012) |
| " Compared with other opioids, low-dose fentanyl has been suggested to produce milder side effects such as nausea, constipation, and somnolence." | 7.77 | [Direct low-dose fentanyl patch (2.1mg) introduction for opioid naïve outpatients with cancer pain]. ( Fujita, S; Fukae, M; Hata, A; Iwamori, S; Kaji, R; Katakami, N; Masuda, Y; Mifune, Y; Nanjo, S; Orita, H; Otsuka, K; Yamatani, T, 2011) |
| " The following data points were collected before and after each naloxone dose; blood pressure, heart rate, respiratory rate, RASS score, pain assessment score (recorded as present or absent), midazolam dose, propofol dose and fentanyl dose." | 7.75 | Safety of enteral naloxone for the reversal of opiate-induced constipation in the intensive care unit. ( Arpino, PA; Thompson, BT, 2009) |
| "The fentanyl transdermal matrix patch is approved in Japan for the management of moderate to severe cancer-related pain in adults." | 7.74 | Fentanyl transdermal matrix patch (Durotep MT patch; Durogesic DTrans; Durogesic SMAT): in adults with cancer-related pain. ( Hoy, SM; Keating, GM, 2008) |
| "TTS-fentanyl can be applied as long-term therapy to patients with cancer-related pain, including the elderly." | 7.71 | Longitudinal follow-up of TTS-fentanyl use in patients with cancer-related pain: results of a compassionate-use study with special focus on elderly patients. ( Desmedt, M; Lossignol, D; Menten, J; Mullie, A, 2002) |
| " In all patient groups, immediate-release oral morphine was the rescue analgesic and lactulose 10 mL twice daily was the prophylaxis of constipation; no antiemetics were used as prophylaxis." | 5.24 | A comparison of oral controlled-release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in cancer patients. ( Leppert, W; Nosek, H; Nosek, K; Onichimowski, D; Wordliczek, J, 2017) |
| "The purpose of this trial was to evaluate the effect of long-term treatment with oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine on nausea, emesis and constipation." | 5.14 | Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine. ( Kloecker, N; Mueller, M; Nadstawek, J; Schaefer, N; Schenk, M; Schroeck, A; Standop, J; Wirz, S; Wittmann, M, 2009) |
| "This study aimed to (1) evaluate the psychometric properties of PAC-SYM in assessing the symptoms and severity of opioid-induced constipation; (2) test for differences in opioid-induced constipation between Durogesic fentanyl transdermal reservoir (TDF) and oral sustained-release morphine (SRM) in patients with chronic low back pain (CLBP)." | 5.12 | Validation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain. ( Dubois, D; Keininger, DL; Simpson, K; Slappendel, R, 2006) |
| "To compare the efficacy and safety of transdermal fentanyl (TDF) and sustained release morphine (SRM) in strong-opioid naïve patients with chronic low back pain (CLBP)." | 5.11 | Transdermal fentanyl versus sustained release oral morphine in strong-opioid naïve patients with chronic low back pain. ( Allan, L; Richarz, U; Simpson, K; Slappendel, R, 2005) |
| "Constipation and the use of laxatives were investigated in patients with chronic cancer pain treated with oral morphine and transdermal fentanyl in an open sequential trial." | 5.09 | Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine. ( Grond, S; Kasper, M; Kulbe, C; Lehmann, KA; Loick, G; Radbruch, L; Sabatowski, R, 2000) |
| "Transdermal Fentanyl (TF, Durogesic) is a strong opioid analgesic which is used in the treatment of cancer pain." | 5.09 | [Research from the Palliative Care Department in Poznań on treatment of neoplasm pain with Durogesic (transdermal fentanyl)]. ( Gorzelińska, L; Kozikowska, J; Leppert, W; Luczak, J, 2000) |
| "The findings indicate comparability of transdermal buprenorphine and transdermal fentanyl for pain measures with significantly fewer adverse events (nausea and treatment discontinuation due to adverse events) caused by transdermal buprenorphine." | 4.88 | Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain. ( Aune, D; Hernandez, AV; Kleijnen, J; Misso, K; Riemsma, R; Truyers, C; Wolff, RF, 2012) |
| "According to the World Health Organization (WHO) guidelines for patients with moderate or severe pain, morphine has been used as a "gold standard" treatment for cancer pain." | 4.82 | [Basic studies on cancer pain control]. ( Narita, M; Niikura, K; Ozaki, M; Suzuki, T; Yajima, Y, 2005) |
| "Antinociceptive actions of NFEPP and fentanyl were compared in control mice and mice with dextran sodium sulfate colitis by measuring visceromotor responses to colorectal distension." | 4.12 | Agonist that activates the µ-opioid receptor in acidified microenvironments inhibits colitis pain without side effects. ( Bok, DD; Bunnett, NW; Degro, C; Guzman-Rodriguez, M; Jaramillo-Polanco, JO; Jensen, DD; Jiménez-Vargas, NN; Latorre, R; Lomax, AE; Lopez, C; Margolis, KG; Reed, DE; Schmidt, BL; Snow, Z; Stein, C; Tsang, Q; Vanner, SJ; Wisdom, M; Yu, Y, 2022) |
| " In this study we evaluated the development and treatment of opioid induced constipation (OIC), and OIC resolving effect of methylnaltrexone for different opioid subtypes in daily clinical practice." | 3.91 | Optimal treatment of opioid induced constipation in daily clinical practice - an observational study. ( Beeker, A; Berkhof, J; Neefjes, ECW; Rhodius, CA; Ten Oever, D; van den Berg, HP; van der Vliet, HJ; van der Vorst, MJDL; van der Wijngaart, H; Verheul, HMW, 2019) |
| " Compared with other opioids, low-dose fentanyl has been suggested to produce milder side effects such as nausea, constipation, and somnolence." | 3.77 | [Direct low-dose fentanyl patch (2.1mg) introduction for opioid naïve outpatients with cancer pain]. ( Fujita, S; Fukae, M; Hata, A; Iwamori, S; Kaji, R; Katakami, N; Masuda, Y; Mifune, Y; Nanjo, S; Orita, H; Otsuka, K; Yamatani, T, 2011) |
| " The following data points were collected before and after each naloxone dose; blood pressure, heart rate, respiratory rate, RASS score, pain assessment score (recorded as present or absent), midazolam dose, propofol dose and fentanyl dose." | 3.75 | Safety of enteral naloxone for the reversal of opiate-induced constipation in the intensive care unit. ( Arpino, PA; Thompson, BT, 2009) |
| "The fentanyl transdermal matrix patch is approved in Japan for the management of moderate to severe cancer-related pain in adults." | 3.74 | Fentanyl transdermal matrix patch (Durotep MT patch; Durogesic DTrans; Durogesic SMAT): in adults with cancer-related pain. ( Hoy, SM; Keating, GM, 2008) |
| "In this population, patients receiving transdermal fentanyl had a lower risk of developing constipation compared with those receiving oxycodone CR or morphine CR." | 3.72 | Incidence of constipation associated with long-acting opioid therapy: a comparative study. ( Markowitz, J; Schein, J; Staats, PS, 2004) |
| "TTS-fentanyl can be applied as long-term therapy to patients with cancer-related pain, including the elderly." | 3.71 | Longitudinal follow-up of TTS-fentanyl use in patients with cancer-related pain: results of a compassionate-use study with special focus on elderly patients. ( Desmedt, M; Lossignol, D; Menten, J; Mullie, A, 2002) |
| "TTS fentanyl was shown to be an effective, safe and simple method for long-term pain relief in cancer patients and presents an interesting novel option in the treatment of cancer pain." | 2.68 | Transdermal fentanyl in combination with initial intravenous dose titration by patient-controlled analgesia. ( Lehmann, KA; Zech, DF, 1995) |
| "Although opioids have been shown to be effective for cancer pain, opioid-induced adverse events (AEs) are common." | 1.91 | Prevalence of opioid-induced adverse events across opioids commonly used for analgesic treatment in Japan: a multicenter prospective longitudinal study. ( Arakawa, S; Chiu, SW; Hiratsuka, Y; Hirayama, H; Inoue, A; Ishiki, H; Kosugi, K; Kubo, E; Matsuda, Y; Miyashita, M; Morita, T; Natsume, M; Nishijima, K; Ouchi, K; Sato, M; Satomi, E; Shigeno, T; Shimizu, M; Shimoda, M; Shimoi, T; Tagami, K; Yamaguchi, T; Yokomichi, N, 2023) |
| "Opioid-induced constipation is the most prevalent adverse effect of opioid drugs." | 1.62 | Pharmacological characterization of naloxegol: In vitro and in vivo studies. ( Calò, G; Costanzini, A; De Giorgio, R; Malfacini, D; Neto, JA; Ruzza, C; Sternini, C; Sturaro, C, 2021) |
| "Antinociception, constipation and respiratory depression were assessed using the warm water tail-flick test, the castor oil-induced diarrhoea test and whole body plethysmography respectively." | 1.42 | In vivo profiling of seven common opioids for antinociception, constipation and respiratory depression: no two opioids have the same profile. ( Kuo, A; Meutermans, W; Smith, MT; Wyse, BD, 2015) |
| "IV-PCA provided timely, safe and useful analgesia for patients with severe breakthrough pain and may be useful to help titration of opioids, weaning to oral analgesia and to decide for interventional procedures." | 1.40 | Safety profile of intravenous patient-controlled analgesia for breakthrough pain in cancer patients: a case series study. ( Ashmawi, HA; Cascudo, GM; de Santana Neto, J; Guimaraes, GM; Neto, JO; Sousa, AM, 2014) |
| "Basing on the components and the endurable dosage of each component for children, we formulated the appropriate dosage and usage of a few analgesics (including sustained release tablets of morphine, oxycodone and transdermal fantanyl) available in China, most of which were used in adults." | 1.34 | [Feasibility to treat pediatric cancer pain with analgesics for adults and their efficacy]. ( Lin, H; Ling, JY; Luo, WB; Sun, XF; Xia, Y; Zhen, ZJ; Zheng, L, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (6.25) | 18.7374 |
| 1990's | 2 (6.25) | 18.2507 |
| 2000's | 12 (37.50) | 29.6817 |
| 2010's | 12 (37.50) | 24.3611 |
| 2020's | 4 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Kondo, A | 1 |
| Murakami, T | 1 |
| Fujii, T | 1 |
| Tatsumi, M | 1 |
| Ueda-Sakane, Y | 1 |
| Ueda, Y | 1 |
| Yamauchi, I | 1 |
| Ogura, M | 1 |
| Taura, D | 1 |
| Inagaki, N | 1 |
| Hiratsuka, Y | 1 |
| Tagami, K | 1 |
| Inoue, A | 1 |
| Sato, M | 1 |
| Matsuda, Y | 1 |
| Kosugi, K | 1 |
| Kubo, E | 1 |
| Natsume, M | 1 |
| Ishiki, H | 1 |
| Arakawa, S | 1 |
| Shimizu, M | 1 |
| Yokomichi, N | 1 |
| Chiu, SW | 1 |
| Shimoda, M | 1 |
| Hirayama, H | 1 |
| Nishijima, K | 1 |
| Ouchi, K | 1 |
| Shimoi, T | 1 |
| Shigeno, T | 1 |
| Yamaguchi, T | 1 |
| Miyashita, M | 1 |
| Morita, T | 1 |
| Satomi, E | 1 |
| Jiménez-Vargas, NN | 1 |
| Yu, Y | 1 |
| Jensen, DD | 1 |
| Bok, DD | 1 |
| Wisdom, M | 1 |
| Latorre, R | 1 |
| Lopez, C | 1 |
| Jaramillo-Polanco, JO | 1 |
| Degro, C | 1 |
| Guzman-Rodriguez, M | 1 |
| Tsang, Q | 1 |
| Snow, Z | 1 |
| Schmidt, BL | 1 |
| Reed, DE | 1 |
| Lomax, AE | 1 |
| Margolis, KG | 1 |
| Stein, C | 2 |
| Bunnett, NW | 1 |
| Vanner, SJ | 1 |
| Costanzini, A | 1 |
| Ruzza, C | 1 |
| Neto, JA | 1 |
| Sturaro, C | 1 |
| Malfacini, D | 1 |
| Sternini, C | 1 |
| De Giorgio, R | 1 |
| Calò, G | 1 |
| Nosek, K | 1 |
| Leppert, W | 2 |
| Nosek, H | 1 |
| Wordliczek, J | 1 |
| Onichimowski, D | 1 |
| Neefjes, ECW | 1 |
| van der Wijngaart, H | 1 |
| van der Vorst, MJDL | 1 |
| Ten Oever, D | 1 |
| van der Vliet, HJ | 1 |
| Beeker, A | 1 |
| Rhodius, CA | 1 |
| van den Berg, HP | 1 |
| Berkhof, J | 1 |
| Verheul, HMW | 1 |
| Gálvez, R | 1 |
| Schäfer, M | 1 |
| Hans, G | 1 |
| Falke, D | 1 |
| Steigerwald, I | 1 |
| Sousa, AM | 1 |
| de Santana Neto, J | 1 |
| Guimaraes, GM | 1 |
| Cascudo, GM | 1 |
| Neto, JO | 1 |
| Ashmawi, HA | 1 |
| Kuo, A | 1 |
| Wyse, BD | 1 |
| Meutermans, W | 1 |
| Smith, MT | 1 |
| Domingo-Triadó, V | 1 |
| López Alarcón, MD | 1 |
| Villegas Estévez, F | 1 |
| Alba Moratillas, C | 1 |
| Massa Domínguez, B | 1 |
| Palomares Payá, F | 1 |
| Mínguez Martí, A | 1 |
| Debón Vicent, L | 1 |
| López-Pérez, FJ | 1 |
| Mínguez-Martí, A | 1 |
| Vicario-Sánchez, E | 1 |
| Pastor-Clérigues, A | 1 |
| Sanfeliu-García, J | 1 |
| Ortega-García, MP | 1 |
| Merchan, C | 1 |
| Altshuler, D | 1 |
| Papadopoulos, J | 1 |
| Spahn, V | 1 |
| Del Vecchio, G | 1 |
| Labuz, D | 1 |
| Rodriguez-Gaztelumendi, A | 1 |
| Massaly, N | 1 |
| Temp, J | 1 |
| Durmaz, V | 1 |
| Sabri, P | 1 |
| Reidelbach, M | 1 |
| Machelska, H | 1 |
| Weber, M | 1 |
| Hoy, SM | 1 |
| Keating, GM | 1 |
| Wirz, S | 1 |
| Wittmann, M | 1 |
| Schenk, M | 1 |
| Schroeck, A | 1 |
| Schaefer, N | 1 |
| Mueller, M | 1 |
| Standop, J | 1 |
| Kloecker, N | 1 |
| Nadstawek, J | 1 |
| Arpino, PA | 1 |
| Thompson, BT | 1 |
| Hata, A | 1 |
| Katakami, N | 1 |
| Masuda, Y | 1 |
| Nanjo, S | 1 |
| Otsuka, K | 1 |
| Kaji, R | 1 |
| Fujita, S | 1 |
| Iwamori, S | 1 |
| Mifune, Y | 1 |
| Orita, H | 1 |
| Fukae, M | 1 |
| Yamatani, T | 1 |
| Nakamura, A | 1 |
| Hasegawa, M | 1 |
| Ito, H | 1 |
| Minami, K | 1 |
| Koike, K | 1 |
| Habu-Tomita, N | 1 |
| Nanba, K | 1 |
| Hamaguchi, K | 1 |
| Noshi, E | 1 |
| Hashimoto, H | 1 |
| Nishino, I | 1 |
| Okabayashi, Y | 1 |
| Koyabu, K | 1 |
| Kihara, T | 1 |
| Iwamoto, Y | 1 |
| Inoue, Y | 1 |
| Narita, M | 2 |
| Suzuki, T | 2 |
| Kato, A | 1 |
| Wolff, RF | 1 |
| Aune, D | 1 |
| Truyers, C | 1 |
| Hernandez, AV | 1 |
| Misso, K | 1 |
| Riemsma, R | 1 |
| Kleijnen, J | 1 |
| Menten, J | 1 |
| Desmedt, M | 1 |
| Lossignol, D | 1 |
| Mullie, A | 1 |
| GARDOCKI, JF | 1 |
| YELNOSKY, J | 1 |
| Staats, PS | 1 |
| Markowitz, J | 1 |
| Schein, J | 1 |
| Radbruch, L | 2 |
| Elsner, F | 1 |
| Slappendel, R | 2 |
| Simpson, K | 2 |
| Dubois, D | 1 |
| Keininger, DL | 1 |
| Yajima, Y | 1 |
| Ozaki, M | 1 |
| Niikura, K | 1 |
| Allan, L | 1 |
| Richarz, U | 1 |
| Zhen, ZJ | 1 |
| Sun, XF | 1 |
| Xia, Y | 1 |
| Ling, JY | 1 |
| Zheng, L | 1 |
| Luo, WB | 1 |
| Lin, H | 1 |
| Zech, DF | 1 |
| Lehmann, KA | 2 |
| Davies, A | 1 |
| Prentice, W | 1 |
| Sabatowski, R | 1 |
| Loick, G | 1 |
| Kulbe, C | 1 |
| Kasper, M | 1 |
| Grond, S | 1 |
| Luczak, J | 1 |
| Gorzelińska, L | 1 |
| Kozikowska, J | 1 |
| Péceli, E | 1 |
| Seres, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Evaluation of the Efficacy of Methylnaltrexone in Resolving Constipation Induced by Different Opioid Subtypes, Combined With Laboratory Analysis of Immunomodulatory and Antiangiogenic Effects of Methylnaltrexone[NCT01955213] | 7 participants (Actual) | Observational | 2012-07-31 | Terminated | |||
| An Evaluation of the Effectiveness and Tolerability of Tapentadol Hydrochloride Prolonged Release, and Tapentadol Hydrochloride Immediate Release on Demand, in Subjects With Severe Chronic Nociceptive, Mixed or Neuropathic Low Back Pain Taking WHO Step II[NCT00986258] | Phase 3 | 136 participants (Actual) | Interventional | 2009-10-30 | Terminated (stopped due to This clinical trial was terminated early, due to slow recruitment and study drug shortages.) | ||
| Methylnaltrexone for the Reversal of Opiate-Induced Constipation in the Intensive Care Unit[NCT01050595] | Phase 3 | 80 participants (Anticipated) | Interventional | 2009-12-31 | Recruiting | ||
| The Use of Oral Naloxone to Prevent Post Spinal Fusion Ileus[NCT03176316] | Phase 4 | 150 participants (Anticipated) | Interventional | 2018-01-02 | Recruiting | ||
| Assessing the Content Validity of a Stool Symptom Screener in Patients With Chronic Opioid-Induced Constipation[NCT01645371] | 79 participants (Actual) | Observational | 2012-08-31 | Completed | |||
| Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicentre, Interventional Clinical Trial to Assess the Efficacy and Safety of the Food Supplement Microsmin® Plus in the Symptomatic Treatment of Haemorrhoids[NCT05750563] | 80 participants (Anticipated) | Interventional | 2023-02-28 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"For this pain assessment, the participant was to indicate the level of average pain experienced over the previous 3 days on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated no pain and a score of 10 indicated pain as bad as you can imagine." (NCT00986258)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Tapentadol Prolonged Release | 4.8 |
"For this pain assessment, the participant was to indicate the level of average pain experienced over the previous 3 days on an 11-point Numerical Rating Scale(NRS) where a score of 0 indicated no pain and a score of 10 indicated pain as bad as you can imagine. The value indicates the change from the baseline value on the 0 to 10 scale. A Negative value indicates a reduction in pain intensity from the baseline average pain intensity." (NCT00986258)
Timeframe: Baseline; End of Week 12 (12 weeks)
| Intervention | units on a scale (Mean) |
|---|---|
| Tapentadol Prolonged Release | -1.3 |
"For this pain assessment, the participant was to indicate the level of average pain experienced over the previous 3 days on an 11-point Numerical Rating Scale(NRS) where a score of 0 indicated no pain and a score of 10 indicated pain as bad as you can imagine. The value indicates the change from the baseline value on the 0 to 10 scale. A negative value indicates a reduction in pain intensity from the baseline average pain intensity." (NCT00986258)
Timeframe: Baseline; End of Week 6 (6 weeks)
| Intervention | units on a scale (Mean) |
|---|---|
| Tapentadol Prolonged Release | -0.9 |
Tapentadol was compared to Buprenorphine with Buprenorphine set to 1. The average total daily dose of Tapentadol at which a pain score equivalent or below to the pain score at the end of observation period under Buprenorphine was reached was documented as the equipotent or equianalgesic dose to the total daily dose of the previously used Buprenorphine. (NCT00986258)
Timeframe: Baseline; End of Week 6 (6 Weeks)
| Intervention | Ratio (Number) |
|---|---|
| Tapentadol | 210.0 |
Tapentadol was compared to Transdermal Fentanyl with Fentanyl set to 1. The average total daily dose of Tapentadol at which a pain score equivalent or below to the pain score at the end of observation period under Transdermal Fentanyl was reached was documented as the equipotent or equianalgesic dose to the total daily dose of the previously used Fentanyl. (NCT00986258)
Timeframe: Baseline; End of Week 6 (6 Weeks)
| Intervention | Ratio (Number) |
|---|---|
| Tapentadol | 250.7 |
Tapentadol was compared to Hydromorphone with Hydromorphone set to 1. The average total daily dose of Tapentadol at which a pain score equivalent or below to the pain score at the end of observation period under Hydromorphone was reached was documented as the equipotent or equianalgesic dose to the total daily dose of the previously used Hydromorphone. (NCT00986258)
Timeframe: Baseline; End of Week 6 (6 Weeks)
| Intervention | Ratio (Number) |
|---|---|
| Tapentadol | 10.5 |
Tapentadol was compared to Morphine with Morphine set to 1. The average total daily dose of Tapentadol at which a pain score equivalent or below to the pain score at the end of observation period under Morphine was reached was documented as the equipotent or equianalgesic dose to the total daily dose of the previously used Morphine. (NCT00986258)
Timeframe: Baseline; End of Week 6 (6 Weeks)
| Intervention | Ratio (Number) |
|---|---|
| Tapentadol | 3.0 |
Tapentadol was compared to Oxycodone with Oxycodone set to 1. The average total daily dose of Tapentadol at which a pain score equivalent or below to the pain score at the end of observation period under Oxycodone was reached was documented as the equipotent or equianalgesic dose to the total daily dose of the previously used Oxycodone. (NCT00986258)
Timeframe: Baseline; End of Week 6 (6 Weeks)
| Intervention | Ratio (Number) |
|---|---|
| Tapentadol | 5.3 |
Participants were considered responders if they reported the same or less average pain intensity over a 3 day period (NRS-3) after 6 weeks of tapentadol prolonged release treatment compared to their previous analgesic treatment (over a 3 day period on the Numeric Rating Scale) at Week 6 compared with Week-1. (NCT00986258)
Timeframe: 6 weeks
| Intervention | participants (Number) |
|---|---|
| Tapentadol Prolonged Release | 76 |
"The painDETECT questionnaire was used to determine the possibility of the presence of a neuropathic pain component. It is a participant completed questionnaire. A total score is calculated. Participants with a score between 0 and 12 are scored as being negative (no neuropathic pain component). Value between 19 and 38 as being positive (presence of neuropathic component). Values from 13 to 18 are scored as being unclear." (NCT00986258)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Baseline painDETECT Negative Group | 6.5 |
| Baseline painDETECT Unclear Group | 14.7 |
| Baseline painDETECT Positive Group | 21.1 |
"The baseline painDETECT score was reassessed at the end of Week 12.~It is a participant completed questionnaire. A total score is calculated. Participants with a score between 0 and 12 are scored as being negative (no neuropathic pain component). Value between 19 and 38 as being positive (presence of neuropathic component). Values from 13 to 18 are scored as being unclear." (NCT00986258)
Timeframe: End of Week 12
| Intervention | units on a scale (Mean) |
|---|---|
| Baseline painDETECT Negative Group | 6.8 |
| Baseline painDETECT Unclear Group | 8.6 |
| Baseline painDETECT Positive Group | 16.5 |
"The baseline painDETECT score was reassessed at the end of Week 6.~It is a participant completed questionnaire. A total score is calculated. Participants with a score between 0 and 12 are scored as being negative (no neuropathic pain component). Value between 19 and 38 as being positive (presence of neuropathic component). Values from 13 to 18 are scored as being unclear." (NCT00986258)
Timeframe: End of Week 6
| Intervention | units on a scale (Mean) |
|---|---|
| Baseline painDETECT Negative Group | 7.5 |
| Baseline painDETECT Unclear Group | 10.5 |
| Baseline painDETECT Positive Group | 17.4 |
The Scores Form 36 (SF-36) includes several brief questions on 8 aspects, (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional and mental health) that a participant was asked to score over the last week. A higher score indicates an improvement in health. All domains are scored on a scale from 0 (negative health) to 100 (positive health), with 100 representing the best possible health state. A positive mean value indicates an improvement from baseline. (NCT00986258)
Timeframe: Baseline; End of Week 12 (12 Weeks)
| Intervention | units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Physical Functioning | Bodily Pain | General Health | Vitality | Social Functioning | Role Emotional | Mental Health | Role Physical | |
| Tapentadol Prolonged Release | 10.5 | 14.1 | 5.7 | 12.0 | 11.7 | 13.9 | 9.8 | 10.7 |
The Scores Form 36 (SF-36) includes several brief questions on 8 aspects, (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional and mental health) that a participant was asked to score over the last week. A higher score indicates an improvement in health. All domains are scored on a scale from 0 (negative health) to 100 (positive health), with 100 representing the best possible health state. A positive mean value indicates an improvement from baseline. (NCT00986258)
Timeframe: Baseline; End of Week 6 (6 Weeks)
| Intervention | units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Physical Functioning | Bodily Pain | General Health | Vitality | Social Functioning | Role Emotional | Mental Health | Role Physical | |
| Tapentadol Prolonged Release | 8.4 | 11.6 | 5.9 | 9.2 | 8.0 | -1.4 | 5.1 | 6.9 |
"All participants were requested to complete the NPSI (Neuropathic Pain Symptom Inventory) questionnaire at this visit. Each participant rated their own neuropathic pain symptoms by answering ten questions relating to neuropathic symptoms on an 11-point scale 0 (not present) to 10 (worst imaginable) for each question. The higher the score for a question (sub-scale) the more bothersome the symptom is for the participant.~Results are reported as the mean (average) for each neuropathic symptom in a sub-scale.~The mean score is reported on a scale of 0 (not present in the group) to 1 (symptom has the maximum imaginable intensity for the whole group)." (NCT00986258)
Timeframe: End of Week 12
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Sub-score burning pain | Sub-score pressing pain | Sub-score paroxysmal pain | Sub-score evoked pain | Sub-score paresthesia / dysthesia | Overall score | |
| Tapentadol Prolonged Release | 0.27 | 0.302 | 0.254 | 0.273 | 0.299 | 0.280 |
"All participants were requested to complete the NPSI (Neuropathic Pain Symptom Inventory) questionnaire at this visit. Each participant rated their own neuropathic pain symptoms by answering ten questions relating to neuropathic symptoms on an 11-point scale 0 (not present) to 10 (worst imaginable) for each question. The higher the score for a question (sub-scale) the more bothersome the symptom is for the participant.~Results are reported as the mean for each neuropathic symptom in a sub-scale. The mean score is reported on a scale of 0 (not present in the group) to 1 (symptom has the maximum imaginable intensity for the whole group)." (NCT00986258)
Timeframe: End of Week 6
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Sub-score burning pain | Sub-score pressing pain | Sub-score paroxysmal pain | Sub-score evoked pain | Sub-score paresthesia / dysthesia | Overall score | |
| Tapentadol Prolonged Release | 0.32 | 0.322 | 0.271 | 0.274 | 0.302 | 0.297 |
"All participants were requested to complete the NPSI (Neuropathic Pain Symptom Inventory) questionnaire at this visit. Each participant rated their own neuropathic pain symptoms by answering ten questions relating to neuropathic symptoms on an 11-point scale 0 (not present) to 10 (worst imaginable) for each question. The higher the score for a question (sub-scale) the more bothersome the symptom is for the participant.~Results are reported as the mean for each neuropathic symptom in the sub-scale. The mean score is reported on a scale of 0 (not present in the group) to 1 (symptom has the maximum imaginable intensity for the whole group)." (NCT00986258)
Timeframe: Baseline
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Sub-score burning pain | Sub-score pressing pain | Sub-score paroxysmal pain | Sub-score evoked pain | Sub-score paresthesia / dysthesia | Overall score | |
| Tapentadol Prolonged Release | 0.41 | 0.405 | 0.422 | 0.385 | 0.424 | 0.408 |
In the Patient Global Impression of Change (PGIC) the participant indicates the perceived change over the treatment period. The participant is requested to choose one of seven categories. Scores range from very much improved to very much worse. (NCT00986258)
Timeframe: Baseline; End of Week 12 (12 Weeks)
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Very much improved | Much improved | Minimally improved | No change | Minimally worse | Much worse | Very much worse | |
| Tapentadol Prolonged Release | 9 | 34 | 38 | 9 | 2 | 1 | 0 |
In the Patient Global Impression of Change (PGIC) the participant indicates the perceived change over the treatment period. The participant is requested to choose one of seven categories. Scores range from very much improved to very much worse. (NCT00986258)
Timeframe: Baseline; End of Week 6 (6 Weeks)
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Very much improved | Much improved | Minimally improved | No change | Minimally worse | Much worse | Very much worse | |
| Tapentadol Prolonged Release | 5 | 29 | 47 | 11 | 6 | 3 | 0 |
3 reviews available for fentanyl and Constipation
| Article | Year |
|---|---|
Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain.
Topics: Administration, Oral; Analgesics, Opioid; Buprenorphine; Chronic Pain; Constipation; Fentanyl; Human | 2012 |
Clinical experience with transdermal fentanyl for the treatment of cancer pain in Germany.
Topics: Administration, Cutaneous; Clinical Trials as Topic; Constipation; Fentanyl; Germany; Humans; Narcot | 2004 |
[Basic studies on cancer pain control].
Topics: Analgesics, Opioid; Animals; Constipation; Dose-Response Relationship, Drug; Fentanyl; Humans; Morph | 2005 |
9 trials available for fentanyl and Constipation
| Article | Year |
|---|---|
A comparison of oral controlled-release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in cancer patients.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Aged, 80 and over; Analgesics, Opioid; Bupren | 2017 |
Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study.
Topics: Adult; Aged; Analgesics, Opioid; Buprenorphine; Chronic Pain; Constipation; Delayed-Action Preparati | 2013 |
[Breakthrough pain treatment with sublingual fentanyl in patients with chronic cutaneous ulcers].
Topics: Administration, Sublingual; Aged; Chronic Disease; Constipation; Female; Fentanyl; Humans; Male; Mid | 2014 |
Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Antiemetics; Buprenor | 2009 |
Validation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; | 2006 |
Validation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; | 2006 |
Validation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; | 2006 |
Validation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; | 2006 |
Transdermal fentanyl versus sustained release oral morphine in strong-opioid naïve patients with chronic low back pain.
Topics: Administration, Cutaneous; Administration, Oral; Analgesics, Opioid; Chronic Disease; Constipation; | 2005 |
Transdermal fentanyl in combination with initial intravenous dose titration by patient-controlled analgesia.
Topics: Administration, Cutaneous; Analgesia, Patient-Controlled; Analgesics; Constipation; Dose-Response Re | 1995 |
Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; | 2000 |
[Research from the Palliative Care Department in Poznań on treatment of neoplasm pain with Durogesic (transdermal fentanyl)].
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; | 2000 |
20 other studies available for fentanyl and Constipation
| Article | Year |
|---|---|
Opioid-induced adrenal insufficiency in transdermal fentanyl treatment: a revisited diagnosis in clinical setting.
Topics: Adrenal Insufficiency; Analgesics, Opioid; Constipation; Female; Fentanyl; Humans; Middle Aged; Neop | 2022 |
Prevalence of opioid-induced adverse events across opioids commonly used for analgesic treatment in Japan: a multicenter prospective longitudinal study.
Topics: Analgesics, Opioid; Cancer Pain; Constipation; Delirium; Fentanyl; Humans; Hydromorphone; Japan; Lon | 2023 |
Agonist that activates the µ-opioid receptor in acidified microenvironments inhibits colitis pain without side effects.
Topics: Animals; Colitis; Colon; Colorectal Neoplasms; Constipation; Fentanyl; Humans; Inflammatory Bowel Di | 2022 |
Pharmacological characterization of naloxegol: In vitro and in vivo studies.
Topics: Administration, Oral; Analgesics, Opioid; Animals; Behavior, Animal; Calcium; CHO Cells; Constipatio | 2021 |
Optimal treatment of opioid induced constipation in daily clinical practice - an observational study.
Topics: Aged; Analgesics, Opioid; Constipation; Female; Fentanyl; Humans; Laxatives; Male; Middle Aged; Nalt | 2019 |
Safety profile of intravenous patient-controlled analgesia for breakthrough pain in cancer patients: a case series study.
Topics: Adult; Analgesia, Patient-Controlled; Analgesics; Breakthrough Pain; Constipation; Female; Fentanyl; | 2014 |
In vivo profiling of seven common opioids for antinociception, constipation and respiratory depression: no two opioids have the same profile.
Topics: Analgesics, Opioid; Animals; Benzeneacetamides; Buprenorphine; Castor Oil; Constipation; Diarrhea; E | 2015 |
[Clinical experience in opioid switch for noncancer chronic pain treatment].
Topics: Adjuvants, Pharmaceutic; Administration, Oral; Aged; Aged, 80 and over; Analgesia, Epidural; Analges | 2014 |
Methylnaltrexone Versus Naloxone for Opioid-Induced Constipation in the Medical Intensive Care Unit.
Topics: Adult; Analgesics, Opioid; Constipation; Critical Illness; Electronic Health Records; Female; Fentan | 2017 |
A nontoxic pain killer designed by modeling of pathological receptor conformations.
Topics: Acute Pain; Adenosine Monophosphate; Analgesia; Analgesics, Opioid; Animals; Computer Simulation; Co | 2017 |
Fentanyl transdermal matrix patch (Durotep MT patch; Durogesic DTrans; Durogesic SMAT): in adults with cancer-related pain.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Area Under Curve; Clinical Trials, Phase II as | 2008 |
Safety of enteral naloxone for the reversal of opiate-induced constipation in the intensive care unit.
Topics: Aged; Analgesics, Opioid; Constipation; Critical Care; Female; Fentanyl; Humans; Intubation, Gastroi | 2009 |
Safety of enteral naloxone for the reversal of opiate-induced constipation in the intensive care unit.
Topics: Aged; Analgesics, Opioid; Constipation; Critical Care; Female; Fentanyl; Humans; Intubation, Gastroi | 2009 |
Safety of enteral naloxone for the reversal of opiate-induced constipation in the intensive care unit.
Topics: Aged; Analgesics, Opioid; Constipation; Critical Care; Female; Fentanyl; Humans; Intubation, Gastroi | 2009 |
Safety of enteral naloxone for the reversal of opiate-induced constipation in the intensive care unit.
Topics: Aged; Analgesics, Opioid; Constipation; Critical Care; Female; Fentanyl; Humans; Intubation, Gastroi | 2009 |
[Direct low-dose fentanyl patch (2.1mg) introduction for opioid naïve outpatients with cancer pain].
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Constipation; Female; Fentanyl; Humans; Male; Mi | 2011 |
Distinct relations among plasma concentrations required for different pharmacological effects in oxycodone, morphine, and fentanyl.
Topics: Analgesics; Analgesics, Opioid; Animals; Brain; Constipation; Dose-Response Relationship, Drug; Fent | 2011 |
Longitudinal follow-up of TTS-fentanyl use in patients with cancer-related pain: results of a compassionate-use study with special focus on elderly patients.
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Constipation; Female; Fentanyl; Follow-Up Studi | 2002 |
A STUDY OF SOME OF THE PHARMACOLOGIC ACTIONS OF FENTANYL CITRATE.
Topics: Analgesics; Analgesics, Non-Narcotic; Antipyretics; Behavior, Animal; Blood Circulation; Blood Press | 1964 |
Incidence of constipation associated with long-acting opioid therapy: a comparative study.
Topics: Aged; Analgesics, Opioid; California; Constipation; Female; Fentanyl; Humans; Incidence; Male; Middl | 2004 |
[Feasibility to treat pediatric cancer pain with analgesics for adults and their efficacy].
Topics: Adolescent; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschool; Co | 2007 |
Re: Fentanyl, morphine, and constipation.
Topics: Analgesics, Opioid; Constipation; Diarrhea; Fentanyl; Humans; Morphine; Substance Withdrawal Syndrom | 1998 |
[Use of neuroleptic analgesia in gynecological interventions].
Topics: Adolescent; Adult; Aged; Benperidol; Blood Transfusion; Constipation; Diuresis; Female; Fentanyl; Ge | 1970 |